PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.2448
https://www.valueinhealthjournal.com/article/S1098-3015(18)35750-4/fulltext
Title :
PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35750-4&doi=10.1016/j.jval.2018.09.2448
First page :
Section Title :
Open access? :
No
Section Order :
1803